![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
Received June 22, 2006; accepted September 11, 2006
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). Presynaptic GABAB receptors, via inhibition of Ca2+ channels, inhibit the release of several neurotransmitters and neuropeptides whereas postsynaptically located receptors activate potassium channels and induce slow inhibitory postsynaptic potentials. GABAB receptors belong to the family C of G protein-coupled receptors (GPCRs) with the agonist binding pocket being constituted by the large N-terminal extracellular domain (ECD). Native GABAB receptors are heterodimers composed of two subunits, GABAB1 (GB1) and GABAB2 (GB2). The receptors are exceptional among GPCR heterodimers in that only one subunit, GB1, constitutes the GABA binding domain, whereas activation of G proteins is mediated only through the second subunit, GB2. Mutagenesis studies and the lack of evolutionary conservation suggest that the ECD of GB2 does not form a binding pocket for a natural ligand (Kniazeff et al., 2002). Genetic inactivation of either the GB1 or the GB2 subunit abolishes physiological GABAB receptor responses demonstrating that GB1 and GB2 are essential subunits of all brain GABAB receptors (Bettler et al., 2004)
Baclofen is a selective GABAB receptor agonist and is used clinically as muscle relaxant (Bowery, 2006). Although GABAB receptors represent a potentially interesting target for several neurological and psychiatric diseases, the exploration and use of baclofen for such indications is hampered by its sedative and muscle relaxant effects. Positive allosteric modulators of GABAB receptors such as CGP7930 and GS39783 have recently been identified (Urwyler et al., 2001, 2003). These molecules enhance both the potency and the maximal efficacy of GABA but have little or no intrinsic agonistic efficacy on their own. In vivo, the effect of positive allosteric modulators are dependent on the endogenously released agonists; thus, the compounds potentiate ongoing synaptic activity only (Christopoulos, 2002; Christopoulos and Kenakin, 2002; Jensen and Spalding, 2004). Therefore, the principle of positive modulation provides an interesting avenue for the development of new pharmacotherapies targeting GABAB receptors, because differential in vivo pharmacological profiles of positive modulators compared with agonists are expected. Indeed, it has been shown that GS39783 lacks the sedative and muscle relaxant properties of baclofen, whereas activity in animal models of drug abuse and anxiety suggest that GABAB receptor positive modulation induces desired pharmacological effects (Cryan et al., 2004; Smith et al., 2004; Slattery et al., 2005).
The binding sites of allosteric inhibitors and positive modulators of several other family C GPCRs have been localized to the transmembrane domain (Litschig et al., 1999; Pagano et al., 2000; Knoflach et al., 2001; Lavreysen et al., 2003; Schaffhauser et al., 2003; Jiang et al., 2005). Binet et al. (2004) recently provided evidence that the GABAB receptor positive modulator CGP7930 interacts with the transmembrane domain of the GB2 subunit; however, specific amino acids important for positive modulator function have not been identified yet.
In the present study, we aimed to characterize the binding site for the GABAB receptor positive modulator GS39783. We used interspecies combinations of receptor subunits from Drosophila melanogaster and rat to map the interaction of GS39783 with the GABAB receptor heterodimer. We identified specific amino acids in the transmembrane domain of GB2 which are important for GS39783 function and show that mutation of selective residues can switch positive modulation to agonistic effects. Our results also support the notion that GB2 subunits can function independently of GB1.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
): dGB1, 5'-CAC CAT GAC AAG TGA TGG TGC TGT TAC G and 5'-TAG TTC CAT GCA CCA GGT ACT CTA CTC; dGB2, 5'-CAC CTC TGG GAC TAA GCA AGC TGC CCA and 5'-CTT GTA GGC GGC GCG AGT CAT ATG. PCRs were carried out using Pfu polymerase (Stratagene, La Jolla, CA; 58°C, 35 cycles, 5-min extension), and the products were cloned into pcDNA3-topo (Invitrogen) and sequenced.
Rat/D. melanogaster GB2 Subunit Chimeras and Point Mutations. Mutant receptor subunits were constructed by PCR (Phusion polymerase; Finnzymes, Espoo, Finland) using the "splicing by overlap extension" method as described previously (Horton et al., 1989). The boundary sequences in rat/D. melanogaster GB2 subunit chimeras were the following: PPKD_RTLI (N terminus rat, TM, and C terminus D. melanogaster) and PPKD_RTII (N terminus D. melanogaster, TM, and C terminus rat). For chimeras within the GB2 transmembrane region, the splice sites were chosen within conserved sequences in the connecting loops: KLIK_MSSP (after TM I); ETLC_TARA (after TM II); KKII_KDYQ (after TM III); YSME_H-HEN (after TM IV); TRNV_SIPA (after TM V); LTRD_RKDL (after TM VI); and LRTN_PQGV (after TM VII). C-terminal hemagglutinin (HA) tags (YPYDVPDYA) were added to mutant subunits containing C-terminal D. melanogaster sequences to facilitate expression analysis by Western blots. For the introduction of point mutations (Fig. 3), two complementary mutant primers sequences were designed (35-45 nucleotides) and used in PCR reactions (25 cycles, 50 ng of template, 62°C annealing) together with forward primer 5'-ATC TCA GGG AAG ACT CCA CAG (rGB2-f) or reverse primer 5-TCC CTC CAG GCG TGA CGT GCT C (rGB2-r). PCR products were joined in a second amplification with primers rGB2-f and rGB2-r (10 cycles). The DNA fragments were gel-purified (Qiaex; Qiagen, Valencia, CA), digested with ApaI/AleI and used to replace a corresponding wild-type ApaI/AleI fragment of rat GB2 cloned into pC1-neo (Promega, Madison, WI). Likewise, rGB1 mutant subunits were constructed using primers 5'-CTG CTC ACTG GCA CTG GCT GC and 5'-GCG GCC GCG CGG CCG CTC AGG GAG ATC CTT CTC CAT G together with mutant primers. Final PCR products were digested with BstEII/NotI and were used to replace a corresponding wild-type fragment of rat GABAB1a in pC1-neo. For the construction of D. melanogaster GB2 (dGB2) point mutations PCRs were done with primers 5'-CTT GTG GAG TAC GAC AGA CTG C (dGB2-f) and 5'-TAC CGA CGT TGG AGC CAC CTG (dGB2-r) together with mutant primers. Joined PCR products were used to replace a BaeI/BstEII fragment of dGB2-HA cloned into pcDNA3.1-topo (Invitrogen). To introduce mutations into chimeric subunits (N-terminal rat, TM D. melanogaster) PCRs were done with primers rGB2-f and dGB2-r, and the ApaI/BstEII-digested products used to replace corresponding wild-type fragments. All constructs were sequenced. For the mutations, the first character and the number indicate amino acid (single letter code) and position of the targeted amino acid, respectively, according to the translations of accessions Y10369
[GenBank]
, AJ011318
[GenBank]
, and AF318273
[GenBank]
, including the signal peptide (rat GABAB1a, rGB2, and dGB2, respectively). The second character indicates the amino acid substitution introduced (from D. melanogaster GB2 or rat GB1). For key amino acids, the numbers according to the generic system proposed by Ballesteros and Weinstein (1995) are indicated in brackets.
|
oA (rat Gnao; NM_017327
[GenBank]
) cloned in pCD-PS (8 µg of plasmid DNA; FuGene; Roche Diagnostics, Indianapolis, IN). For expression of heteromeric GABAB receptors, 2 to 3 µg of GB1, 1 to 2 µg of GB2, and 4 µg of GoA were used; to express GB2 subunits individually, 4 µg of GB2 and 4 µgofGoA were used. Cells were harvested 2 days after transfection. The cells were scraped off the dishes in phosphate-buffered saline, homogenized using glass-glass homogenizers, and centrifuged for 30 min at 4°C at 20,000g. After resuspension in buffer, the pellet was rehomogenized and centrifuged again. Membranes were resuspended in [35S]GTP
S binding assay buffer, the protein concentrations were determined using a BCA protein assay kit (Novagen, Madison, WI), and the membranes were used immediately in [35S]GTPS binding assays.
[35S]GTPS Binding Assay. The assay mixtures contained 10 to 40 µg of membranes in 50 mM Tris-HCl buffer, pH 7.7, 10 mM MgCl2, 1.8 mM CaCl2, 100 mM NaCl, 10 µM GDP (Sigma, St. Louis, MO), 0.2 nM [35S]GTPS, and test compounds (Urwyler et al., 2001). Ninety-six-well Packard Pico plates (300 µl volume; PerkinElmer Life and Analytical Sciences Boston, MA) were used. The reagents were incubated for 60 min at room temperature and were subsequently filtered (Packard unifilter GF/C). After two washes with assay buffer as above, the plates were dried for 1 h at 50°C, 50 µl of scintillation solution (Microscint) was added, and the radioactivity was counted. Counts were normalized to 20 µg of membrane protein. Prism 3.0 or 4.0 software (GraphPad Software Inc., San Diego, CA) was used for all data calculations. Basal levels were determined in the absence of test compounds. In all figures except for Fig. 1, signals are expressed as counts per minute above basal. The data points in figures are means (± S.E.M.) calculated from triplicate determinations. Statistical comparisons were done using a t test (two-tailed, unpaired; p < 0.05 was considered significant).
|
Western Blot. Cell membrane preparations were resuspended in sample buffer [62.5 mM Tris, pH 6.8, 2% (w/v) SDS, 0.01% (w/v) bromphenol blue, 5% (v/v) 
-mercaptoethanol, and 25% glycerol], shaken for 45 min at room temperature, and loaded onto 7.5% SDS-acrylamide gels (Bio-Rad, Hercules, CA). After electrophoretic transfer, the membranes were incubated for 1 h at room temperature in phosphate-buffered saline containing 0.1% Tween 20 and 5% fat-free powdered milk. Antibody AbC22 (directed against C-terminal sequences of rGB2; Kaupmann et al., 1998) was applied overnight at 4°C in phosphate-buffered saline containing 0.1% Tween 20 and 5% fat-free powdered milk. Incubation with horseradish peroxidase-conjugated anti-rabbit antibody (Cell Signaling, Beverly, MA) was for 1 h at room temperature. For detection of HA-tagged dGB2, a peroxidase-conjugated anti-HA antibody (Roche) was applied overnight at 4°C. Peroxidase activity was detected using Supersignal West Pico substrate (Pierce, Rockford, IL) and Kodak MR-1 X-ray films (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Compounds. GS39783 and CGP7930 were synthesized in house. Stock solutions (10 mM) were prepared in dimethyl sulfoxide and subsequently diluted in assay buffer. GABA was obtained from Fluka (Buchs, Switzerland); 100 mM stock solutions were prepared in H2O.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
S binding assays (Fig. 1). GABA at 1 or 20 µM significantly stimulated [35S]GTPS binding using native GABAB receptor preparations from different vertebrate species and with membranes from cells expressing cloned D. melanogaster GABAB receptors. In the presence of GS39783, the GABA signal was enhanced at rat, fish, and chicken but not at D. melanogaster GABAB receptors (Fig. 1a). Concentration-response curves (CRCs) support the conclusion that rat but not D. melanogaster GABAB receptors are positively modulated by GS39783 (Fig. 1, b and c).
|
To investigate further which receptor domains are important for positive modulation, D. melanogaster/rat GB2 subunit chimeras were constructed and investigated in functional [35S]GTPS binding assays (Fig. 2). With a first set of GB2 subunit chimeras, we aimed to show whether the binding site of GS39783 resides within the seven transmembrane (TM) region or the ECD of the GB2 subunit. A GB2 subunit chimera in which the ECD of dGB2 was fused to the TM region of rGB2 was positively modulated by GS39783, upon coexpression with either rat or D. melanogaster GB1 (Fig. 2a). The stimulation levels for the application of GABA in the presence of GS39783 were significantly higher than the levels obtained with GABA applied alone (p < 0.05 versus 1 mM GABA, n = 3). The converse chimera (i.e., the ECD of rGB2 fused to the TM domain of dGB2) yielded functional receptors responsive to activation by GABA but which were not positively modulated by GS39783. These data indicated that the TM-spanning region or C-terminal intracellular sequences of rGB2 are critical for positive modulation. No significant stimulation with GABA or GS39783 was observed when rGB2 subunit chimeras were expressed without GB1.
To further delineate which part of the TM region is important for positive modulation, mutant GB2 subunits were generated in which individual TM helices (TM1-7) of rGB2 where introduced into the D. melanogaster TM region. As a template, a chimera was used in which the ECD from rGB2 was fused to the TM region of dGB2 (Fig. 2b). Receptors containing this chimeric GB2 subunit were not responsive to GS39783 (Fig. 2a); hence, we hypothesized that by successive addition of TM helices from rGB2, positive modulation by GS39783 would be gained at one point. However, none of the mutants that contained TM helices from both D. melanogaster and rat yielded functional receptors, as shown by the lack of stimulation with GABA in the [35S]GTPS binding assay (Fig. 2b). Therefore, these mutants were not informative for the GS39783 mapping purpose. Only after all TMs from rGB2 had been introduced (Fig. 2b), stimulation by GABA was obtained, and receptors containing this mutant subunit were positively modulated by GS39783 as expected. The C-terminal intracellular sequence of this mutant subunit was derived from D. melanogaster, thus excluding the C-terminal rGB2 sequence for being important for GS39783 function.
Identification of Individual Amino Acids in the GB2 TM Domain Affecting GS39783 Function. The abovementioned data suggested that subtle changes (i.e., point mutations) were required to further elucidate which transmembrane helices are critical for positive modulation. To identify candidate amino acids, a sequence alignment of TMs from rat and D. melanogaster GB2 together with different family C GPCRs was used (Fig. 3a). Candidate residues for mutagenesis were identified based on the following criteria: 1) conservation in rat but not D. melanogaster GB2; or 2) conservation in rGB2 but not in rGB1. rGB1 and rGB2 subunits share only 42% sequence-identical amino acids in the TM region, and the similarity between rat and D. melanogaster GB2 is also very limited (52% identical residues in the TM). Therefore many amino acids fulfill the "candidate" criteria as above. We investigated amino acids in TMs 2 to 7 with a focus on residues that have been shown previously to be involved in the binding of allosteric modulators to other family 3 GPCRs (Jensen and Spalding, 2004). Respective candidate amino acids in rGB2 were mutated to the corresponding residues present in dGB2 or to the corresponding residue present in rGB1. By using this approach, we expected to obtain functional rGB2 subunits which, upon coexpression with rGB1, are not positively modulated if the mutated amino acid is crucial for GS39783 activity. A summary of all amino acids investigated (>50) is shown in Fig. 3b. Whenever possible, several adjacent point mutations were combined in one construct. Each rGB2 mutant was transiently coexpressed in HEK293FT cells together with rGB1 and cell membranes analyzed in [35S]GTPS binding assays. To assess positive modulation by GS39783, the stimulatory effect of 10 µM GABA in the presence of 10 µM GS39783 was compared with the response obtained with 10 µM GABA applied alone. The signal obtained with GABA applied alone serves as a readout for functionality of the mutant protein. In addition, the effect of 10 µM GS39783 applied alone was measured (Fig. 3b).
GABA stimulated [35S]GTPS binding at the majority of rGB1/mutant rGB2 heterodimers confirming the functionality of the rGB2 proteins (Fig. 3b). Receptors containing an rGB2 mutant subunit (G706T, A708P, and S710T in TM 6) were considerably activated by GS39783 when the modulator was applied without GABA (p < 0.01 versus basal; two-tailed t test, unpaired). In this mutant, corresponding residues from rGB1 had been introduced. Heterodimeric receptors containing another rGB2 mutant subunit with three amino acid substitutions at the extracellular face of TM7 (N718D, V719L, and Q720T) were functionally activated by GABA, but the response was not significantly enhanced in the presence of GS39783 (p = 0.21). In this rGB2 subunit, three amino acids were mutated to corresponding residues in dGB2. A few mutant subunits did not yield to considerable functional activation by GABA in the [35S]GTPS binding assay, although the expression of GB2 subunit was confirmed by Western blots (data not shown). At all other functional mutants, GS39783 did not stimulate significantly when applied alone but enhanced the GABA signal. Although absolute stimulation levels varied, probably dependent on expression levels, we concluded that the most likely GS39783 function is not affected in these mutants.
|
|
S binding assay for the mutant G706T, A708P, and S710T in TM6 after coexpression with wild-type rGB1 are shown in Fig. 4, a and b. GABA application in the absence and presence of modulator revealed that GS39783 significantly increased the potency and maximal efficacy of GABA (Fig. 4a and Table 1) but also stimulated [35S]GTPS binding when applied alone. In contrast, GS39783 did not stimulate [35S]GTPS binding at wild-type receptors when applied alone but significantly increased GABA potency and efficacy as expected (Fig. 4e). CRCs for GS39783 confirmed the stimulation of [35S]GTPS binding in the absence or presence of 10 µM GABA (Fig. 4b), stimulation which was not observed at wild-type receptors (Fig. 4f). The basal counts in [35S]GTPS binding assays were not significantly different from wild-type receptors (data not shown), suggesting that the mutations introduced did not markedly affect constitutive receptor activity. It is noteworthy that the TM6 mutations introduced led to a somewhat increased GABA potency compared with wild-type controls, whereas the potency of GS39783 in modulating the GABA response was similar (Table 1). In summary, these data suggested a switch to agonistic activity of GS39783 at GABAB heterodimers containing this mutated rGB2 subunit.
|
We have also generated a number of point mutations in dGB2 aimed to generate "gain of function" mutants. Mutations were introduced into wild-type dGB2 and the mutants coexpressed with dGB1. Selected mutations (e.g., the mutations in TM7 described above) were also constructed into a GB2 subunit chimera (ECD from rat, TM from D. melanogaster; Fig. 2) and coexpressed with rGB1. Susceptibility to GS39783, however, was not obtained (data not shown).
The Mutant Subunit rGB2(G706T, A708P, S710T) Is Activated by GS39783 in the Absence of GB1. We further investigated the rGB2(G706T, A708P, S710T) mutant in TM6 in [35S]GTPS binding assays without coexpression of rGB1 (Fig. 5). To our surprise, GS39783 concentration-dependently activated this mutant subunit when expressed alone, whereas wild-type rGB2 subunits were not activated (Fig. 5a). The EC50 values for the agonistic effect of GS39783 was 1.0 ± 0.2 µM(n = 3), which was in a range similar to its EC50 value for positive modulatory activity at rGB1/rGB2 heterodimers (0.3 µM, Table 1). To ensure that no endogenous GB1 subunits were present in the membrane preparation used, we also measured GABA responses (Fig. 5b). GABA-induced [35S]GTPS binding was not observed using membranes from rGB2(G706T, A708P, S710T) and wild-type rGB2-transfected cells (Fig. 5b). This rules out the presence of GB1 in the membrane preparation used and supports previous observations that GABA does not bind to the GB2 subunit (Kniazeff et al., 2002). We concluded that the mutant rGB2 subunit G706T, A708P, and S710T can be activated by GS39783 independently of the GB1 subunit.
Mutations of G706T (6.51) and A708P (6.53) in rGB2 Are Necessary to Confer Agonistic Activity to GS39783. To identify which of the point mutations introduced into rGB2(G706T, A708P, S710T) are important to confer agonistic activity to GS39783, mutant subunits containing all possible permutations of the three amino acid exchanges were constructed and analyzed (Fig. 6). After coexpression with rGB1, GABA-stimulated [35S]GTPS binding and positive modulation by GS39783 were observed with all constructs, confirming functionality of the mutant rGB2 proteins (Fig. 6a). When expressed without GB1 the rGB2(G706T, A708P, S710T) mutant was activated by GS39783 as expected. A combination of G706T (6.51) and A708P (6.53) mutations in rGB2 led to similar activation levels, whereas GS38783 was inactive at all other combinations, including single point mutations (Fig. 6b and Table 1). It is noteworthy that the activation of mutant rGB2 subunits by GS39783 in this assay is substantial. The stimulation levels of 10 µM GS39783 at mutant subunits were similar to the effect of 10 µM GABA in the presence of GS39783 at rGB1/rGB2 heterodimers (Fig. 6b). In summary, these data showed that the mutations in rGB2 of G706T and A708P are necessary and sufficient to confer agonistic activity to GS39783 and render the rGB2 subunit active independently of GB1.
|
), on the rGB2 mutants described above (Fig. 6c). CGP7930 significantly activated both rGB2(G706T, A708P, S710T) and rGB2(G706T, A708P) (p < 0.01; n = 4); however, the agonistic efficacy was reduced to approximately 25% of the response obtained with GS39783. The mutations introduced (glycine > threonine and alanine > proline) are conservative exchanges. Nonconservative mutations at these positions (G706D and A708D) did not result in functional receptors upon coexpression with rGB1 (data not shown). In rGB2(G706T, A708P, S710T), corresponding amino acids present in rGB1 had been introduced. Thus, the observation that the agonistic activity is gained by these mutations is surprising and raises the question of whether there may be a binding site for GS39783 also on the GB1 subunit. We constructed the reverse mutations in rGB1 [threonine > glycine (6.51); proline > alanine (6.53)]; however, when coexpressed with rGB2, we did not observe significant differences compared with wild-type receptors (data not shown).
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The combination of dGB1 and rGB2 subunits yielded functional GABAB receptor heterodimers activated by GABA, whereas the reverse combination, rGB1 coexpressed with dGB2, was not functional. However, functionality was obtained when rGB1 was coexpressed with D. melanogaster/rat GB2 subunit chimeras containing either the N-terminal or the transmembrane/C-terminal part from rat GB2 (Fig. 2). GABAB receptor heterodimer formation is mediated via interactions between C-terminal coiled-coil motifs of GB1 and GB2 subunits but also involves allosteric contact sites between the TM and extracellular sequences. In fact, the deletion of coiled-coil motifs in GB1 and GB2 does not prevent heterodimer formation, emphasizing the importance of additional contacts between subunits (Pagano et al., 2001). The observation that functional receptors can be generated by the interspecies subunit combinations as above was unexpected because the sequence conservation between rat and D. melanogaster subunits is very limited (51 and 44% identical residues for GB1 and GB2, respectively; best-fit alignment). It is likely that the contact sites between subunits are evolutionarily highly conserved between species, and further investigation of sequence conservation in D. melanogaster and rat subunits could provide a strategy to identify residues critical for heterodimer formation.
We attempted to further delineate the binding site of GS39783 using D. melanogaster/rat GB2 chimeras with junctions within the TM region (Fig. 2b); however, none of these chimeras yielded functional receptors after coexpression with GB1. The limited sequence conservation (52% identical residues in TM) may impair functional interactions between TM helices from the different species. Certainly, it is not possible to generalize from our observations that functional GB2 subunits combining TMs from D. melanogaster and rat cannot be generated in principle. The precise junctions and composition may be critical, and only a few chimeras have been generated so far.
A set of rGB2 point mutations were constructed, some of which affected GS39783 function. When coexpressed with rGB1, a mutant rGB2 subunit with three amino acids substitutions in transmembrane domain 6 was considerably activated by GS39783 in the absence of GABA. Surprisingly, in contrast to wild-type rGB2, this mutant was also activated by GS39783 when expressed without GB1. The mutations G706T (6.51) and A708P (6.53) are necessary and sufficient for activation and identify a key region for the effect of GS39783 in TM6 of the rGB2 subunit. It is noteworthy that homologous residues in metabotropic glutamate receptor mGluR1, in the calcium-sensing receptor and in serotonin receptors, have been demonstrated previously to be involved in the effects of negative allosteric modulators and inverse agonists (Joubert et al., 2002; Malherbe et al., 2003; Hu et al., 2006). Furthermore, Surgand et al. (2006) predicted based on chemogenomic analysis of TM-binding cavities of GPCRs that small-sized GABAB allosteric modulators might interact with TM6 residues 6.48 or 6.51. Our data support the validity of these predictions and emphasize the importance of TM6 for the effects of the positive modulator GS39783.
The molecular effects of the amino acid substitutions introduced on positive modulator binding and receptor activation, however, are not understood to date. An important question is whether the aforementioned residues are directly involved in GS39783 binding or whether the mutations have indirect effects, such as facilitation or alteration of GS39783-induced conformational changes of the TM helices. Because the key mutations introduced above did not abolish GS39783 function, a definite answer to this question is not yet possible. A caveat is that the low (micromolar) potency of currently available positive modulator compounds such as GS39783 does not allow the use of respective radioligand derivatives to investigate whether binding affinities are affected. In the functional GTPS binding assay used in this study, nonconservative mutations at positions 6.48 and 6.51 in rGB2(G706D, A708D) disrupted not only GS39783 but also GABA responses; therefore, conclusions as to whether GS39783 binding was impaired are not possible. It is noteworthy that the rGB2(G706T, A708P) mutations induced agonistic activity of GS39783 but did not alter its potency in positively modulating GABA responses at heterodimeric receptors (Table 1). Therefore, the mutations identify critical residues important for agonism rather than positive modulation. In support of a key role of TM6 for allosteric modulation, modeling studies by Malherbe et al. (2003) suggest that conserved amino acids in TM6 of metabotropic glutamate receptors are key for the transition between allosteric states. In addition to G706T (6.51) and A708P (6.53) identified in this study, it is likely that additional amino acids in other TMs are important for GS39783 function. These residues could be conserved between subunits and species and therefore could have escaped identification by the strategy used in this study. Our observation that the rGB2(N718D, V719L, Q720T) mutations affected efficacy but not potency of positive modulation by GS39783 may suggest the importance of ligand interactions at the extracellular face of TM7.
In the rGB2(G706T, A708P) mutant subunit, amino acids were exchanged to the corresponding homologs present in rGB1 (Fig. 3). The observation that these mutations did not impair but rather induced responsiveness to GS39783 was therefore very surprising. It remains possible that GS39783 also binds to the rGB1 subunit. On the other hand, in the present study, we did not obtain additional evidence for GS39783 interaction with GB1. The potency of GS39783 on rGB1/rGB2 heterodimers was similar compared with its potency on mutant rGB2 subunits (Table 1). Because the GB1 subunit does not activate effector systems (Margeta-Mitrovic et al., 2001), binding assays with more potent positive modulator radioligands are required to further elucidate whether there is also a molecular interaction with GB1.
In a recent study, Binet et al. (2004) reported the activation of wild-type GB2 subunits by a different positive modulator compound, CGP7930, which led to the conclusion that the modulator in fact is a partial GB2 agonist. In the present study, GS39783 did not activate at all individually expressed GB2 subunits, and agonistic activity was strictly dependent on the mutations introduced as described above. Furthermore, even at coexpressed wild-type rGB1 and rGB2 subunits, significant agonistic activity of GS39783 (ago-allosterism; Schwartz and Holst, 2006) was not observed. It is likely that apparent partial agonistic activity of positive modulator compounds depends on the expression systems used and requires assays with considerable receptor reserve, such as the inositol phosphate production assay used by Binet et al. (2004). Similar observations have been made for both CGP7930 and GS39783 in a cAMP assay using a cell line stably expressing GABAB receptors (Urwyler et al., 2005). However, the lack of significant agonistic activity of GS39783 observed in the present study is in agreement with in vitro assays (Urwyler et al., 2003) and with in vivo experiments in which orally applied GS39783 lacked effects on its own but, together with a threshold concentration of the agonist baclofen, significantly decreased cAMP formation in the rat striatum in a dose-dependent fashion (Gjoni et al., 2006).
The observation that two conservative mutations in GB2 conferred agonistic activity to a synthetic compound has several implications. In support of the previous notion (Binet et al., 2004), our data suggest that GB2 subunits may function independently of GB1. The developmental regulation and localization of GB1 and GB2 subunits in the brain do not always match precisely (Bettler et al., 2004). It remains to be investigated whether GB2 fulfills receptor functions independently of GB1 in vivo. Critical residues for agonistic activation of GB2 subunits by GS39783 were identified in TM6. This may indicate the conservation of binding site cavities for allosteric enhancers between GABAB receptors and other family C GPCRs. Homology modeling and docking studies are therefore warranted. Furthermore, it seems evident that significant activation of GABAB receptors may be achieved via agonism at the GB2 subunit. Therefore, the GB2 subunit may represent a useful site for developing novel GABAB receptor agonists.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: GPCR, G protein-coupled receptor; CRC, concentration-response curve; ECD, N-terminal extracellular domain; GB1 and GB2, GABAB1 and GABAB2 subunits, respectively; dGB1 and dGB2, D. melanogaster GABAB receptor subunits GABAB1 and GABAB2, respectively; rGB1, rGB2, rat GABAB receptor subunits GABAB1, GABAB2, respectively; GS39783, N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine; [35S]GTPS, guanosine 5'-O-(3-[35S]thio)triphosphate; HA, hemagglutinin; HEK, human embryonic kidney; mGluR, metabotropic glutamate receptor; TM, transmembrane; CGP7930, 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol; PCR, polymerase chain reaction.
1 Current affiliation: Institut de Recherches Servier, Croissy/Seine, France. 
2 Current affiliation: The Babraham Institute, Babraham, Cambridge, United Kingdom.
3 Current affiliation: Lectus Therapeutics Ltd., Babraham, Cambridge, United Kingdom.
Address correspondence to: Dr. Klemens Kaupmann, Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-125.7.42, CH-4002 Basel, Switzerland. E-mail: klemens.kaupmann{at}novartis.com
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Bettler B, Kaupmann K, Mosbacher J, and Gassmann M (2004) Molecular structure and physiological functions of GABAB receptors. Physiol Rev 84: 835-867.
Binet V, Brajon C, Le Corre L, Acher F, Pin JP, and Prezeau L (2004) The heptahelical domain of GABAB2 is activated directly by CGP7930, a positive allosteric modulator of the GABAB receptor. J Biol Chem 279: 29085-29091.
Bowery NG (2006) GABAB receptor: a site of therapeutic benefit. Curr Opin Pharmacol 6: 37-43.[CrossRef][Medline]
Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1: 198-210.[CrossRef][Medline]
Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoehl K, Froestl W, Bettler B, Kaupmann K, and Spooren WP (2004) Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310: 952-963.
Gjoni T, Desrayaud S, Imobersteg S, and Urwyler S (2006) The positive allosteric modulator GS39783 enhances GABAB receptor-mediated inhibition of cyclic AMP formation in rat striatum in vivo. J Neurochem 96: 1416-1422.[CrossRef][Medline]
Horton RM, Hunt HD, Ho SN, Pullen JK, and Pease LR (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77: 61-68.[CrossRef][Medline]
Hu J, Jiang J, Costanzi S, Thomas C, Yang W, Feyen JH, Jacobson KA, and Spiegel AM (2006) A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J Biol Chem 281: 21558-21565.
Jensen A and Spalding S (2004) Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci 21: 407-420.[CrossRef][Medline]
Jiang P, Cui M, Zhao B, Liu Z, Snyder LA, Benard LM, Osman R, Margolskee RF, and Max M (2005) Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J Biol Chem 280: 15238-15246.
Joubert L, Claeysen S, Sebben M, Bessis AS, Clark RD, Martin RS, Bockaert J, and Dumuis A (2002) A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem 277: 25502-25511.
Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, et al. (1998) GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature (Lond) 396: 683-687.[CrossRef][Medline]
Kniazeff J, Galvez T, Labesse G, and Pin JP (2002) No ligand binding in the GB2 subunit of the GABAB receptor is required for activation and allosteric interaction between the subunits. J Neurosci 22: 7352-7361.
Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, and Kemp JA (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci USA 98: 13402-13407.
Lavreysen H, Janssen C, Bischoff F, Langlois X, Leysen JE, and Lesage AS (2003) [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 63: 1082-1093.
Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prezeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55: 453-461.
Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, Maerki HP, Adam G, and Mutel V (2003) Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 278: 8340-8347.
Margeta-Mitrovic M, Jan YN, and Jan LY (2001) Function of GB1 and GB2 subunits in G protein coupling of GABAB receptors. Proc Natl Acad Sci USA 98: 14649-14654.
Mezler M, Muller T, and Raming K (2001) Cloning and functional expression of GABAB receptors from Drosophila. Eur J Neurosci 13: 477-486.[CrossRef][Medline]
Pagano A, Rovelli G, Mosbacher J, Lohmann T, Duthey B, Stauffer D, Ristig D, Schuler V, Meigel I, Lampert C, et al. (2001) C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABAb receptors. J Neurosci 21: 1189-1202.
Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezeau L, Carroll F, Pin JP, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275: 33750-33758.
Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64: 798-810.
Schwartz TW and Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26: 107-128.[CrossRef][Medline]
Slattery DA, Markou A, Froestl W, and Cryan JF (2005) The GABAB receptorpositive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology 30: 2065-2072.[CrossRef][Medline]
Smith MA, Yancey DL, Morgan D, Liu Y, Froestl W, and Roberts DC (2004) Effects of positive allosteric modulators of the GABAB receptor on cocaine selfadministration in rats. Psychopharmacology (Berl) 173: 105-111.[CrossRef][Medline]
Surgand JS, Rodrigo J, Kellenberger E, and Rognan D (2006) A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62: 509-538.[CrossRef][Medline]
Urwyler S, Gjoni T, Koljatic J, and Dupuis DS (2005) Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 48: 343-353.[CrossRef][Medline]
Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, Bettler B, and Kaupmann K (2001) Positive allosteric modulation of native and recombinant gamma-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 60: 963-971.
Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, Koller M, and Kaupmann K (2003) N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine GS39783) and structurally related compounds: novel allosteric enhancers of -aminobutyric acid B receptor function. J Pharmacol Exp Ther 307: 322-330.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
